Gap Junction Protein
Gap junction (GJ) channels span the plasma membranes of adjacent cells and are formed by the docking of two hemichannels (connexons) oligomerized from connexin (Cx) proteins, which consist of 21 distinct isoforms. GJs provide a direct pathway for cell-to-cell electrical signaling and metabolic communication, allowing the passage of small ions, amino acids, metabolites, tetraethylammonium and signaling molecules such as cAMP, IP3, siRNA and small peptide.
Gap junction channels provide the basis for intercellular communication in the cardiovascular system for maintenance of the normal cardiac rhythm, regulation of vascular tone and endothelial function as well as metabolic interchange between the cells. In the heart, GJs mediate electrical coupling between cardiac myocytes, forming the cell-to-cell pathways for orderly spread of the wave of electrical excitation responsible for synchronous contraction. Gap junctions also play an important role in the control of bladder contractile response and in the regulation of various immune inflammatory processes.
All Product Categories
-
Gap Junction Protein Related Products (49)
Related Products (49)
-
Antibodies (14)
-
Peptide5
0 ImagesPeptide5, a connexin 43 mimetic peptide, reduce animals swelling, astrogliosis, and neuronal cell death after spinal cord injury
-
Larazotide
0 ImagesLarazotideis a peptide which is an orally active zonulin antagonist. Larazotide shows antiviral activity to varicella-zoster virus (VZV) with EC50s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively. Larazotide can be used for the research of celiac disease and infection.
-
VRT-534
0 ImagesVRT-534 (Compound 3) is a chemical chaperone targeting connexin 26 (Cx26). Vrt-534 exhibits dose-responsive binding to recombinant WT Cx26 and mutant Cx26 K188N with EC50s of 19 and 5 μM, respectively. Vrt-534 can be used in research related to hearing impairment.
-
Zifogaptide
0 ImagesZifogaptide is a gap junction protein channel regulator. Zifogaptide mimics the PDZ-binding motif at the C-terminal of Claudin C and competitively interferes with the interaction between Claudin–TJP1 (ZO-1) scaffold. Zifogaptide can promote epithelial cell migration, reduce scar formation, and accelerate wound healing. Zifogaptide can be used for radiation dermatitis, skin injuries, etc.
-
Cx43 HC-IN-1
0 ImagesCx43 HC-IN-1 (Compound D4) is a selective and orally active inhibitor of connexin hemichannels (Cx43 HC). Cx43 HC-IN-1 effectively inhibits the hemichannel activity mediated by Cx43/Cx45 in denervated skeletal muscle fibers, significantly increasing the reinnervation rate of muscle fibers by neurons. Cx43 HC-IN-1 reduces neuroinflammation and neuronal overexcitation by inhibiting hemichannels in glial cells in the brain, and alleviates epilepsy in mice. Cx43 HC-IN-1 can be used for research on epilepsy and muscle diseases.
-
Connexin mimetic peptide 40GAP27
0 ImagesConnexin mimetic peptide 40GAP27 is a biological active peptide. (This peptide corresponds to the GAP27 domain of the second extracellular loop of dominant vascular connexin (Cx40), designated as 40Gap 27. It was used to investigate mechanisms through which oxidant stress impairs communication via gap junctions. When administered, 40Gap27attenuates endothelium-dependent subintimal smooth muscle hyperpolarization.)
-
Danegaptide
0 ImagesCat. No.: HY-10913CAS No.: 943134-39-2Synonyms: GAP-134; ZP 1609Danegaptide (GAP-134) is a potent, selective and orally active gap-junction modifier with an antiarrhythmic effect.
-
(R,R)-VRT-534
0 ImagesCat. No.: HY-149318BCAS No.: 926664-33-7(R,R)-VRT-534 is the (R,R)-enantiomer of VRT-534 (HY-149318). VRT-534 (Compound 3) is a chemical chaperone targeting connexin 26 (Cx26). Vrt-534 exhibits dose-responsive binding to recombinant WT Cx26 and mutant Cx26 K188N with EC50s of 19 and 5 μM, respectively. Vrt-534 can be used in research related to hearing impairment.
-
Meclofenamic acid-d4
0 ImagesCat. No.: HY-117275SCAS No.: 1185072-18-7Synonyms: Meclofenamate-d4Meclofenamic acid-d4 is the deuterium labeled Meclofenamic acid. Meclofenamic Acid (Meclofenamate), a non-steroidal, anti-inflammatory agent, is a highly selective fat mass and obesity-associated (FTO) enzyme inhibitor. Meclofenamic Acid competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid is a non-selective gap-junction blocker.
-
Anti-CLDN9 Antibody
0 ImagesCat. No.: HY-P992221Anti-CLDN9 Antibody is a monoclonal antibody targeting CLDN9. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CLDN9 Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
-
AT-1002
0 ImagesCat. No.: HY-114426CAS No.: 835872-35-0AT-1002, a 6-mer synthetic peptide, is a tight junction regulator and absorption enhancer.
-
Hydroxyflutamide (Standard)
0 ImagesCat. No.: HY-W013272RCAS No.: 52806-53-8Synonyms: HFT (Standard)Hydroxyflutamide (Standard) (HFT (Standard)) is the analytical standard of Hydroxyflutamide (HY-W013272). This product is intended for research and analytical applications. Hydroxyflutamide (HFT) is the active metabolite of Flutamide (HY-B0022) and exhibits oral activity. Hydroxyflutamide is a potent androgen receptor antagonist with an IC50 of 700 nM. Hydroxyflutamide can affect embryonic development and reproductive tract development in mice. Additionally, Hydroxyflutamide can enhance the efficacy of Bacillus Calmette-Guérin (BCG) to better inhibit the progression of bladder cancer. Hydroxyflutamide can be used in research related to tumors and reproductive diseases.
-
ALMB-0168
0 ImagesCat. No.: HY-P992010ALMB-0168 is a Cx43 hemichannel agonist monoclonal antibody. ALMB-0168 activates Cx43 hemichannels to inhibit the growth and migration of osteosarcoma. ALMB-0168 is applicable to relevant research on osteosarcoma.
-
Tellimagrandin I
0 ImagesCat. No.: HY-N7764CAS No.: 79786-08-6Tellimagrandin I is a gap junction protein 43 (Cx43) activator, which is a hydrolyzable ellagitannin (ellagitannin) secondary metabolite extractable from various plants. Tellimagrandin I mainly restores gap junction intercellular communication (GJIC) and induces S-phase arrest in tumor cells by upregulating Cx43; activates inflammatory cells to release TNF-α and VEGF to promote angiogenesis in vivo; and protects DNA from damage via antioxidant and metal chelating effects. Tellimagrandin I can be used in research related to human cervical cancer.
-
Carbenoxolone-d4
0 ImagesCat. No.: HY-B1588SPurity: 99.28%Carbenoxolone-d4 is the d4 labeled Carbenoxolone (HY-B1588). Carbenoxolone is a blood-brain barrier-permeable Pannexin1 inhibitor, gap junction (Gap junction) blocker, and β-amyloid 42 inhibitor. Carbenoxolone modulates voltage-gated currents of wild-type and mutant Panx1, and inhibits stimulus-activated Panx1 channel function. Carbenoxolone interacts with stable residues of β-amyloid 42 peptides, fibrils and oligomers, thereby inhibiting their aggregation. Carbenoxolone alleviates liver fibrosis. Carbenoxolone exerts neuroprotective and nootropic effects. Carbenoxolone can be used in studies related to Alzheimer's disease and liver fibrosis.
-
ACT1
0 ImagesCat. No.: HY-P11197CAS No.: 895547-36-1ACT1 is a peptide that targets endogenous Cx43 by stabilizing its activity at gap junctions. ACT1 stabilizes gap junction intercellular communication in breast cancer cells. ACT1 enhances the activity of Tamoxifen (HY-13757A) and Lapatinib (HY-50898) in breast cancer. ACT1 can be used for breast cancer research.
-
Meclofenamic acid-13C6
0 ImagesCat. No.: HY-117275S1Synonyms: Meclofenamate-13C6Meclofenamic acid-13C6 is the 13C6 labeled Meclofenamic acid. Meclofenamic Acid (Meclofenamate), a non-steroidal, anti-inflammatory agent, is a highly selective fat mass and obesity-associated (FTO) enzyme inhibitor. Meclofenamic Acid competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid is a non-selective gap-junction blocker.
-
Osemitamab (FUT8-KO)
0 ImagesCat. No.: HY-P9991AOsemitamab (FUT8-KO) is an anti-claudin-18.2 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study.
